Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Find More News Related to Agreements
In 2025, space has become a pivotal domain for military operations. Nations are investing heavily…
Prime Minister Narendra Modi inaugurated the Rising North East Investors Summit 2025 at Bharat Mandapam,…
In a significant development in India’s marine export sector, Ram Mohan M K has been…
In a landmark fiscal development, the Reserve Bank of India (RBI) has approved a record…
Naval Special Operations Forces represent the most elite and versatile warriors within any country's military…
Corn is one of the most important crops in the United States. It is used…
![](data:image/svg+xml;charset=utf-8,<svg height="195px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="34px" width="156px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
